AMLX
NASD Amylyx Pharmaceuticals, Inc.$28.15 ↑ +0.37 (+1.33%) Trading Up from the previous close of $27.78, and at the day’s high of $28.09
- YTD change
- +133.03%
- vs 20-day SMA
- -10.58%
- vs 200-day SMA
- +52.03%
Price ranges
Price & Performance
+11.97 (+75.66%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 32.9% away from all-time highs of $41.93
- AMLX is up 133% since the beginning of the year
- AMLX is up 110% over the past 12 months
- AMLX is down 17% over the past 1 month
- 12% of all AMLX investors are betting against AMLX
AMLX reads not so good: price sits above one of the two key moving averages, the 12-month move is +119.0%.
- Previous minute
- +$0.00
- Last hour
- +$0.15
- Last 5 days
- -4.54%
- vs 8-day SMA
- -3.90%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of therapies for diseases with significant unmet medical need, with an emphasis on endocrine and neurodegenerative disorders. Its program, avexitide, is a once-daily GLP-1 receptor antagonist being developed for the treatment of post-bariatric hypoglycemia. Amylyx’s pipeline also includes investigational programs targeting Wolfram syndrome and amyotrophic lateral sclerosis (ALS). The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
